Sanofi Is ‘Working On’ Resolving England’s Sarclisa Funding Concerns
Executive Summary
NICE is not yet convinced that Sanofi’s recently approved combination treatment for relapsed or refractory multiple myeloma is value for money. Temporary funding under the Cancer Drugs Fund has also been ruled out.